Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1

Hari S. Conjeevaram, Michael W. Fried, Lennox J Jeffers, Norah A. Terrault, Thelma E. Wiley-Lucas, Nezam Afdhal, Robert S. Brown, Steven H. Belle, Jay H. Hoofnagle, David E. Kleiner, Charles D. Howell

Research output: Contribution to journalArticle

418 Citations (Scopus)

Abstract

Background & Aims: Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy. Methods: In a multicenter treatment trial, 196 AA and 205 CA treatment-naive patients with hepatitis C virus (HCV) genotype 1 infection were treated with peginterferon alfa-2a (180 μg/wk) and ribavirin (1000-1200 mg/day) for up to 48 weeks. The primary end point was sustained virologic response (SVR). Results: Baseline features were similar among AA and CA, including HCV-RNA levels and histologic severity, but AA had higher body weights, a higher prevalence of diabetes and hypertension, and lower alanine transaminase levels (P < .001 for all). The SVR rate was 28% in AA and 52% in CA (P < .0001). Racial differences in viral responses were evident as early as treatment week 4. Breakthrough viremia was more frequent among AA than CA (13% vs 6%, P = .05); relapse rates were comparable (32% vs 25%, P = .30). Proportions of patients with serious adverse events and dose modifications and discontinuations were similar among AA and CA. In multiple regression analyses, CA had a higher SVR rate than AA (relative risk, 1.96; 95% confidence interval, 1.48-2.60; P < .0001). Other factors independently associated with higher SVR included female sex, lower baseline HCV-RNA level, less hepatic fibrosis, and more peginterferon taken. Conclusions: AA with chronic hepatitis C genotype 1 have lower rates of virologic response to peginterferon and ribavirin than CA. These differences are not explained by disease characteristics, baseline viral levels, or amount of medication taken.

Original languageEnglish
Pages (from-to)470-477
Number of pages8
JournalGastroenterology
Volume131
Issue number2
DOIs
StatePublished - Aug 1 2006

Fingerprint

Ribavirin
Hepatitis C
African Americans
Genotype
Hepacivirus
Therapeutics
Chronic Hepatitis C
RNA
Viremia
Alanine Transaminase
Interferons
Multicenter Studies
Antiviral Agents
Fibrosis
Body Weight
Regression Analysis
Confidence Intervals
Hypertension
Recurrence
Sustained Virologic Response

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Conjeevaram, H. S., Fried, M. W., Jeffers, L. J., Terrault, N. A., Wiley-Lucas, T. E., Afdhal, N., ... Howell, C. D. (2006). Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1. Gastroenterology, 131(2), 470-477. https://doi.org/10.1053/j.gastro.2006.06.008

Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1. / Conjeevaram, Hari S.; Fried, Michael W.; Jeffers, Lennox J; Terrault, Norah A.; Wiley-Lucas, Thelma E.; Afdhal, Nezam; Brown, Robert S.; Belle, Steven H.; Hoofnagle, Jay H.; Kleiner, David E.; Howell, Charles D.

In: Gastroenterology, Vol. 131, No. 2, 01.08.2006, p. 470-477.

Research output: Contribution to journalArticle

Conjeevaram, HS, Fried, MW, Jeffers, LJ, Terrault, NA, Wiley-Lucas, TE, Afdhal, N, Brown, RS, Belle, SH, Hoofnagle, JH, Kleiner, DE & Howell, CD 2006, 'Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1', Gastroenterology, vol. 131, no. 2, pp. 470-477. https://doi.org/10.1053/j.gastro.2006.06.008
Conjeevaram, Hari S. ; Fried, Michael W. ; Jeffers, Lennox J ; Terrault, Norah A. ; Wiley-Lucas, Thelma E. ; Afdhal, Nezam ; Brown, Robert S. ; Belle, Steven H. ; Hoofnagle, Jay H. ; Kleiner, David E. ; Howell, Charles D. / Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1. In: Gastroenterology. 2006 ; Vol. 131, No. 2. pp. 470-477.
@article{52cee8a0d6334d2598cc442e5365d046,
title = "Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1",
abstract = "Background & Aims: Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy. Methods: In a multicenter treatment trial, 196 AA and 205 CA treatment-naive patients with hepatitis C virus (HCV) genotype 1 infection were treated with peginterferon alfa-2a (180 μg/wk) and ribavirin (1000-1200 mg/day) for up to 48 weeks. The primary end point was sustained virologic response (SVR). Results: Baseline features were similar among AA and CA, including HCV-RNA levels and histologic severity, but AA had higher body weights, a higher prevalence of diabetes and hypertension, and lower alanine transaminase levels (P < .001 for all). The SVR rate was 28{\%} in AA and 52{\%} in CA (P < .0001). Racial differences in viral responses were evident as early as treatment week 4. Breakthrough viremia was more frequent among AA than CA (13{\%} vs 6{\%}, P = .05); relapse rates were comparable (32{\%} vs 25{\%}, P = .30). Proportions of patients with serious adverse events and dose modifications and discontinuations were similar among AA and CA. In multiple regression analyses, CA had a higher SVR rate than AA (relative risk, 1.96; 95{\%} confidence interval, 1.48-2.60; P < .0001). Other factors independently associated with higher SVR included female sex, lower baseline HCV-RNA level, less hepatic fibrosis, and more peginterferon taken. Conclusions: AA with chronic hepatitis C genotype 1 have lower rates of virologic response to peginterferon and ribavirin than CA. These differences are not explained by disease characteristics, baseline viral levels, or amount of medication taken.",
author = "Conjeevaram, {Hari S.} and Fried, {Michael W.} and Jeffers, {Lennox J} and Terrault, {Norah A.} and Wiley-Lucas, {Thelma E.} and Nezam Afdhal and Brown, {Robert S.} and Belle, {Steven H.} and Hoofnagle, {Jay H.} and Kleiner, {David E.} and Howell, {Charles D.}",
year = "2006",
month = "8",
day = "1",
doi = "10.1053/j.gastro.2006.06.008",
language = "English",
volume = "131",
pages = "470--477",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1

AU - Conjeevaram, Hari S.

AU - Fried, Michael W.

AU - Jeffers, Lennox J

AU - Terrault, Norah A.

AU - Wiley-Lucas, Thelma E.

AU - Afdhal, Nezam

AU - Brown, Robert S.

AU - Belle, Steven H.

AU - Hoofnagle, Jay H.

AU - Kleiner, David E.

AU - Howell, Charles D.

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Background & Aims: Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy. Methods: In a multicenter treatment trial, 196 AA and 205 CA treatment-naive patients with hepatitis C virus (HCV) genotype 1 infection were treated with peginterferon alfa-2a (180 μg/wk) and ribavirin (1000-1200 mg/day) for up to 48 weeks. The primary end point was sustained virologic response (SVR). Results: Baseline features were similar among AA and CA, including HCV-RNA levels and histologic severity, but AA had higher body weights, a higher prevalence of diabetes and hypertension, and lower alanine transaminase levels (P < .001 for all). The SVR rate was 28% in AA and 52% in CA (P < .0001). Racial differences in viral responses were evident as early as treatment week 4. Breakthrough viremia was more frequent among AA than CA (13% vs 6%, P = .05); relapse rates were comparable (32% vs 25%, P = .30). Proportions of patients with serious adverse events and dose modifications and discontinuations were similar among AA and CA. In multiple regression analyses, CA had a higher SVR rate than AA (relative risk, 1.96; 95% confidence interval, 1.48-2.60; P < .0001). Other factors independently associated with higher SVR included female sex, lower baseline HCV-RNA level, less hepatic fibrosis, and more peginterferon taken. Conclusions: AA with chronic hepatitis C genotype 1 have lower rates of virologic response to peginterferon and ribavirin than CA. These differences are not explained by disease characteristics, baseline viral levels, or amount of medication taken.

AB - Background & Aims: Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy. Methods: In a multicenter treatment trial, 196 AA and 205 CA treatment-naive patients with hepatitis C virus (HCV) genotype 1 infection were treated with peginterferon alfa-2a (180 μg/wk) and ribavirin (1000-1200 mg/day) for up to 48 weeks. The primary end point was sustained virologic response (SVR). Results: Baseline features were similar among AA and CA, including HCV-RNA levels and histologic severity, but AA had higher body weights, a higher prevalence of diabetes and hypertension, and lower alanine transaminase levels (P < .001 for all). The SVR rate was 28% in AA and 52% in CA (P < .0001). Racial differences in viral responses were evident as early as treatment week 4. Breakthrough viremia was more frequent among AA than CA (13% vs 6%, P = .05); relapse rates were comparable (32% vs 25%, P = .30). Proportions of patients with serious adverse events and dose modifications and discontinuations were similar among AA and CA. In multiple regression analyses, CA had a higher SVR rate than AA (relative risk, 1.96; 95% confidence interval, 1.48-2.60; P < .0001). Other factors independently associated with higher SVR included female sex, lower baseline HCV-RNA level, less hepatic fibrosis, and more peginterferon taken. Conclusions: AA with chronic hepatitis C genotype 1 have lower rates of virologic response to peginterferon and ribavirin than CA. These differences are not explained by disease characteristics, baseline viral levels, or amount of medication taken.

UR - http://www.scopus.com/inward/record.url?scp=33746535101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746535101&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2006.06.008

DO - 10.1053/j.gastro.2006.06.008

M3 - Article

C2 - 16890601

AN - SCOPUS:33746535101

VL - 131

SP - 470

EP - 477

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 2

ER -